Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are aged 18 to 75 years old at the time of joining the trial
• People who have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) at stage II or III, confirmed by a laboratory test on a tissue or cell sample, and whose cancer is considered removable by surgery
• People whose medical team has assessed them as suitable for pre-surgery treatment using a combination of immune-based therapy and platinum-based chemotherapy, followed by surgery
• People who are largely independent and able to carry out daily activities, with little to no limitation from their illness (this is measured using a standard scale called ECOG, scores 0 or 1)
• People who have not yet received any cancer treatment for their current lung cancer diagnosis
• People whose bone marrow, liver, kidneys, and heart are functioning at an adequate level based on local laboratory tests
• People who are willing and able to attend scheduled appointments and follow the study plan
• People who have read and signed a consent form before joining the trial

Who may not be able to join:

• People whose lung cancer has specific genetic changes known as EGFR-sensitive mutations (such as exon 19del or L858R) or ALK/ROS1 rearrangements (confirm with trial site if unsure about genetic test results)
• People who have cancer that has spread to the brain and is causing symptoms or is not under control
• People who have been diagnosed with another type of cancer in the past 3 years, except for certain skin cancers or a very early form of cervical cancer that have been fully treated
• People who have previously received any systemic cancer treatment — such as immunotherapy, chemotherapy, or targeted therapy — for lung cancer
• People who have had a severe allergic reaction (Grade 3 or higher) to a class of cancer immunotherapy drugs called PD-1 or PD-L1 inhibitors
• People who have an active autoimmune disease that requires ongoing medication to suppress the immune system
• People who have an active infection, including active hepatitis B, hepatitis C, or HIV
• People who are currently pregnant or breastfeeding
• People who have another serious or uncontrolled health condition that the trial doctor believes could interfere with participation or pose too great a risk

Important: Always verify eligibility with the trial site directly before applying.